The Efficacy and Safety of Fecal Microbiota Transplant for Recurrent Clostridiumdifficile Infection: Current Understanding and Gap Analysis

por Wilcox, Mark H, McGovern, Barbara H, Hecht, Gail A
Publicado 2020

Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy

por Badri, Prajakta S., King, Jennifer R., Polepally, Akshanth R., McGovern, Barbara H., Dutta, Sandeep, Menon, Rajeev M.
Publicado 2015

653. Rapid Change in Microbiome Profiles Regardless of Diagnostic Method in a Post Hoc Comparative Analysis of Phase 3 Trials of Fecal Microbiota Spores, Live-brpk (formerly SER-10...

por Gonzales-Luna, Anne J, Litcofsky, Kevin, Straub, Tim, Hot, Dina, McGovern, Barbara, Hasson, Brooke, Sims, Matthew, Ford, Christopher, Henn, Matthew
Publicado 2023

Manufacturing Process of SER-109, a Purified Investigational Microbiome Therapeutic, Reduces Risk of Coronavirus Transmission From Donor Stool

por McChalicher, Christopher, Abdulaziz, Ahmad, Zhou, S Steve, Lombardo, Mary-Jane, Hasson, Brooke, Auniņš, John G, McGovern, Barbara H, Ege, David S
Publicado 2022

658. Diagnostic Testing Among Patients with Suspected Recurrent Clostridioides difficile Infection (rCDI) in ECOSPOR III a Phase 3 Clinical Trial: Implications for Clinical Practic...

por Sims, Matthew, Khanna, Sahil, Pardi, Darrell, Feuerstadt, Paul, Berenson, Charles, Wu, Henry, Wang, Elaine E, Wang, Elaine E, McGovern, Barbara, von Moltke, Lisa
Publicado 2021

1035. Manufacturing Processes of SER-109, a Purified Investigational Microbiome Therapeutic, Reduce Risk of Transmission of Emerging and Undetected Infections in Donor Stool

por McChalicher, Christopher, Abdulaziz, Ahmad, Halvorsen, Elizabeth, Lombardo, Mary-Jane, Winkler, Jonathan, Almomani, Sanabel, McGovern, Barbara, McKenzie, Gregory, Ege, David, Aunins, John
Publicado 2021

Healthcare resource utilization in a phase 3 trial of SER-109 in patients with recurrent Clostridioides difficile infection

por Cohen, Stuart, Louie, Thomas, Berenson, Charles, Amin, Alpesh, Lombardi, David, Pham, Sissi, Huang, Shirley, Wang, Elaine, Hasson, Brooke, McGovern, Barbara, Von Moltke, Lisa
Publicado 2022

1641. Treatment of Recurrent Clostridium difficile Infection With SER-109 Reduces Gastrointestinal Carriage of Antimicrobial Resistance Genes

por Ford, Christopher, Henn, Matthew, Bryant, Jessica, Diao, Liyang, Wortman, Jennifer, Tomlinson, Amelia, Litcofsky, Kevin, Bernardo, Patricia, McGovern, Barbara, Aunins, John G, Cook, David N, Trucksis, Michele
Publicado 2018

655. Analysis of Microbiome Diversity and Secondary Bile Acid Synthesis Following SER-109 or Placebo in Patients with First Recurrent or Multiply Recurrent Clostridioides difficile...

por Kelly, Colleen R, Kraft, Colleen S, Straub, Tim, Litcofsky, Kevin, Wortman, Jennifer R, Cohen, Stuart H, Berenson, Charles, McGovern, Barbara, Hasson, Brooke, Hot, Dina, Pardi, Darrell, Ford, Christopher, Henn, Matthew
Publicado 2023

Manufacturing Processes of a Purified Microbiome Therapeutic Reduce Risk of Transmission of Potential Bacterial Pathogens in Donor Stool

por McChalicher, Christopher W J, Lombardo, Mary-Jane, Khanna, Sahil, McKenzie, Gregory J, Halvorsen, Elizabeth M, Almomani, Sanabel, Schuster, Brian, Hasson, Brooke R, McGovern, Barbara H, Ege, David S, Auniņš, John G
Publicado 2023

621. Treatment of Recurrent Clostridium difficile Infection with SER-109 Increases the Concentration of Secondary Bile Acids in a Dose-Dependent Manner

por Henn, Matthew, Ford, Christopher, O’Brien, Edward, Wortman, Jennifer, Diao, Liyang, Desjardins, Christopher, Tomlinson, Amelia, Litcofsky, Kevin, Wilcox, Mark, Buckley, Anthony, Bernardo, Patricia, McGovern, Barbara, Aunins, John G, Cook, David N, Trucksis, Michele
Publicado 2018

1503. Engraftment of Investigational Microbiome Drug, SER-262, in Subjects Receiving Vancomycin Is Associated with Reduced Rates of Recurrence after Primary Clostridium Difficile I...

por Ford, Christopher, Litcofsky, Kevin, McGovern, Barbara, Pardi, Darrell, Nathan, Richard, Hansen, Val, Brennan, Robert, Pullman, John, Bernardo, Patricia, Tomlinson, Amelia, Horgan, Kevin, Bryant, Jessica, Walsh, Emily, Rodriguez, Michelle, Rogalin, Henry, Wang, Elaine, Henn, Matt
Publicado 2019

Efficacy and Safety of Investigational Microbiome Drug SER-109 for Treatment of Recurrent Clostridioides difficile Infection

por McGovern, Barbara, Sims, Mathew, Kraft, Colleen, Wang, Elaine, Brady, Kelly, Ford, Christopher, Edward, O’Brien, Lombardo, Mary-Jane, Wortman, Jennifer, Litcofsky, Kevin, Mahoney, Jennifer, McChalicher, Christopher, Winkler, Jonathan, Garant, Sarah, Aunins, John, Henn, Matthew, von Moltke, Lisa
Publicado 2021

Broadly directed virus-specific CD4(+) T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence

por Schulze zur Wiesch, Julian, Ciuffreda, Donatella, Lewis-Ximenez, Lia, Kasprowicz, Victoria, Nolan, Brian E., Streeck, Hendrik, Aneja, Jasneet, Reyor, Laura L., Allen, Todd M., Lohse, Ansgar W., McGovern, Barbara, Chung, Raymond T., Kwok, William W., Kim, Arthur Y., Lauer, Georg M.
Publicado 2012

Interferon Lambda 4 Genotype Is Associated With Jaundice and Elevated Aminotransferase Levels During Acute Hepatitis C Virus Infection: Findings From the InC3 Collaborative

por Page, Kimberly, Mirzazadeh, Ali, Rice, Thomas M., Grebely, Jason, Kim, Arthur Y., Cox, Andrea L., Morris, Meghan D., Hellard, Margaret, Bruneau, Julie, Shoukry, Naglaa H., Dore, Gregory J., Maher, Lisa, Lloyd, Andrew R., Lauer, Georg, Prins, Maria, McGovern, Barbara H.
Publicado 2016

Integrated efficacy analysis from phase 3 studies of investigational microbiome therapeutic, SER-109, in recurrent Clostridioides difficile infection

por Sims, Matthew, Silverman, Michael, Louie, Thomas, Wang, Elaine, Kraft, Colleen, Ramesh, Mayur, Bogdanovich, Tatiana, Brady, Kelly, Lombardi, David, Memisoglu, Asli, De, Ananya, Hasson, Brooke, Lee, Christine, Feuerstadt, Paul, Pardi, Darrell, Kelly, Colleen, Daley, Peter, Oguchi, Godson, McGovern, Barbara, Moltke, Lisa Von
Publicado 2023

Integrated safety analysis of phase 3 studies for investigational microbiome therapeutic, SER-109, in recurrent CDI

por Sims, Matthew, Berenson, Charles, Cohen, Stuart, Wang, Elaine, Hohmann, Elizabeth, Nathan, Richard, Odio, Alberto, Cook, Paul, Brady, Kelly, Lombardi, David, Memisoglu, Asli, De, Ananya, Hasson, Brooke, Lashner, Bret, Korman, Louis, Grimard, Doria, Gutierrez, Juan Carlos Moises, McGovern, Barbara, Moltke, Lisa Von
Publicado 2023

Assessment of Quality of Life Among Patients With Recurrent Clostridioides difficile Infection Treated with Investigational Oral Microbiome Therapeutic SER-109: Secondary Analysis...

por Garey, Kevin W., Jo, Jinhee, Gonzales-Luna, Anne J., Lapin, Brittany, Deshpande, Abhishek, Wang, Elaine, Hasson, Brooke, Pham, Sissi V., Huang, Shirley P., Reese, Pat Ray, Wu, Henry, Hohmann, Elizabeth, Feuerstadt, Paul, Oneto, Caterina, Berenson, Charles S., Lee, Christine, McGovern, Barbara, vonMoltke, Lisa
Publicado 2023

Patterns of Hepatitis C Virus RNA Levels during Acute Infection: The InC(3) Study

por Hajarizadeh, Behzad, Grady, Bart, Page, Kimberly, Kim, Arthur Y., McGovern, Barbara H., Cox, Andrea L., Rice, Thomas M., Sacks-Davis, Rachel, Bruneau, Julie, Morris, Meghan, Amin, Janaki, Schinkel, Janke, Applegate, Tanya, Maher, Lisa, Hellard, Margaret, Lloyd, Andrew R., Prins, Maria, Dore, Gregory J., Grebely, Jason
Publicado 2015

Prevalence of Comorbid Factors in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota–Based Therapeutic

por Berenson, Charles S, Lashner, Bret, Korman, Louis Y, Hohmann, Elizabeth, Deshpande, Abhishek, Louie, Thomas J, Sims, Matthew, Pardi, Darrell, Kraft, Colleen S, Wang, Elaine E L, Cohen, Stuart H, Feuerstadt, Paul, Oneto, Caterina, Misra, Bharat, Pullman, John, De, Ananya, Memisoglu, Asli, Lombardi, David A, Hasson, Brooke R, McGovern, Barbara H, von Moltke, Lisa, Lee, Christine H
Publicado 2023